Cytokinetics and Coherus BioSciences Stocks Rise, Iovance Biotherapeutics Falls

T-Mobile issues shares to SoftBank, New York Times sues OpenAI and Microsoft over chatbot training

Cytokinetics Inc. shares rose after the company provided an encouraging update on the development of a potential heart condition treatment.
Coherus BioSciences Inc.'s delivery system for its cancer drug Udenyca received U.S. regulatory approval, leading to a rise in its stock price.
Iovance Biotherapeutics Inc. paused a study on a potential lung cancer treatment due to a safety issue, causing its stock to fall.
T-Mobile US Inc. is issuing over 48.7 million shares of its stock to SoftBank as part of a merger deal with Sprint.
The New York Times Co. filed a federal lawsuit against OpenAI and Microsoft, seeking to end the practice of using its stories to train chatbots.